MedTrace Logo

Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study

NCT00309712 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2008-08-21

No results posted yet for this study

Summary

The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of \<200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.

Conditions

  • Type II Diabetes Mellitus
  • Mixed Dyslipidemia

Interventions

DRUG

fenofibrate 160 mg and placebo

DRUG

simvastatin 20 mg and placebo

DRUG

fenofibrate 160 mg and simvastatin 20 mg

Sponsors & Collaborators

Principal Investigators

  • Joseph B Muhlestein, MD · Intermountain Health Care, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00309712 on ClinicalTrials.gov